Complete financial analysis of GC Cell Corporation (144510.KQ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GC Cell Corporation, a leading company in the industry within the sector.
You may be interested
- Fujian Snowman Co., Ltd. (002639.SZ) Income Statement Analysis – Financial Results
- Eurogas International Inc. (EGINF) Income Statement Analysis – Financial Results
- Ether Capital Corporation (ETHC.NE) Income Statement Analysis – Financial Results
- Hyundai Rotem Company (064350.KS) Income Statement Analysis – Financial Results
- Falcon’s Beyond Global, Inc. 8% Series A Preferred Stock (FBYDP) Income Statement Analysis – Financial Results
GC Cell Corporation (144510.KQ)
Website: https://www.gccell.com
About GC Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in November 2021. GC Cell Corporation was founded in 2011 and is based in Yongin, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 187.54B | 236.12B | 168.31B | 85.56B | 57.90B |
| Cost of Revenue | 132.41B | 139.17B | 99.61B | 62.27B | 43.50B |
| Gross Profit | 55.14B | 96.95B | 68.70B | 23.29B | 14.40B |
| Gross Profit Ratio | 29.40% | 41.06% | 40.82% | 27.22% | 24.87% |
| Research & Development | 24.68B | 26.43B | 18.49B | 13.96B | 15.11B |
| General & Administrative | 4.54B | 2.47B | 1.96B | 339.22M | 37.13M |
| Selling & Marketing | 5.22B | 5.44B | 3.56B | 357.72M | 217.73M |
| SG&A | 9.76B | 7.91B | 5.52B | 696.95M | 2.35B |
| Other Expenses | 16.62B | 69.74M | 557.56M | 94.18M | 0.00 |
| Operating Expenses | 51.06B | 52.67B | 32.28B | 16.82B | 18.29B |
| Cost & Expenses | 183.46B | 191.84B | 131.89B | 79.10B | 61.79B |
| Interest Income | 806.54M | 886.16M | 383.94M | 372.93M | 769.49M |
| Interest Expense | 3.41B | 2.48B | 559.04M | 247.22M | 245.77M |
| Depreciation & Amortization | 15.64B | 13.62B | 7.40B | 4.18B | 4.11B |
| EBITDA | 11.58B | 57.90B | 43.80B | 10.55B | 984.55M |
| EBITDA Ratio | 6.18% | 22.77% | 28.70% | 10.93% | 1.50% |
| Operating Income | 4.08B | 44.28B | 36.34B | 6.43B | -3.24B |
| Operating Income Ratio | 2.17% | 18.75% | 21.59% | 7.52% | -5.60% |
| Total Other Income/Expenses | -11.54B | -7.77B | 3.19B | -1.05B | -120.30M |
| Income Before Tax | -7.46B | 36.51B | 39.53B | 5.38B | -3.37B |
| Income Before Tax Ratio | -3.98% | 15.46% | 23.49% | 6.29% | -5.83% |
| Income Tax Expense | -7.54B | 10.79B | 9.47B | 1.29B | 1.14B |
| Net Income | -174.01M | 24.99B | 31.42B | 4.16B | -2.28B |
| Net Income Ratio | -0.09% | 10.58% | 18.67% | 4.86% | -3.93% |
| EPS | -12.00 | 1.66K | 2.79K | 394.00 | -216.00 |
| EPS Diluted | -11.58 | 1.66K | 2.78K | 394.00 | -216.00 |
| Weighted Avg Shares Out | 14.50M | 15.02M | 11.28M | 10.56M | 10.54M |
| Weighted Avg Shares Out (Dil) | 15.02M | 15.03M | 11.29M | 10.56M | 10.54M |
No news found for: 144510.KQ
Source: https://incomestatements.info
Category: Stock Reports